A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...

The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

The startup’s first prospect is a heart medicine that works differently than the hypertrophic cardiomyopathy drugs developed ...

Already facing headwinds caused by a patient’s death and treatment delays, the biotech now may have to contend with a less ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

The Food and Drug Administration should look for ways to streamline regulations on new U.S. drug manufacturing facilities to ...

The advisory committee meeting is an important step in the process of readying boosters for the fall and winter season, but ...

A vocal opponent of his predecessor Peter Marks, Vinay Prasad will now lead the office tasked with reviewing some genetic ...

Experts say market turmoil has made it harder for buyers and sellers to agree on price, which can be an especially imposing ...

While updated study results confirmed the drug lowers a target protein, the therapy's effect on clinical outcomes was less ...

The cuts to three advanced drug programs were “inevitable” given the company’s “unsustainable cash burn,” one analyst wrote ...